Evidence Level
Fisetin is a flavonoid that has garnered attention for its diverse health benefits. It was identified as a senotherapeutic agent in a study by Yousefzadeh et al. (2018), where it demonstrated significant clearance of senescent cells both in vitro and in vivo, leading to extended late-life lifespan in mice. Additionally, fisetin has shown neuroprotective effects through its modulation of p25 and inflammatory pathways, as reported by Currais et al. (2014), which maintained cognitive function in Alzheimer's disease transgenic mice.
Recent systematic reviews have further elucidated fisetin's potential across various therapeutic areas. Jiang et al. (2023) reviewed evidence highlighting its neuroprotective effects across multiple neurological diseases, while Prem et al. (2022) analyzed 15 studies and concluded that fisetin reduces oxidative stress and inflammation in myocardial ischemia-reperfusion injury, though its efficacy may depend on dosage and comorbidities.
Despite its promising properties, fisetin's poor oral bioavailability remains a challenge. However, Krishnakumar et al. (2022) reported that novel formulations, such as hybrid-hydrogel, could enhance its bioavailability and pharmacokinetics, potentially overcoming this limitation.
Ongoing clinical trials, including the Mayo Clinic AFFIRM trial, are exploring fisetin's efficacy in elderly women with frailty markers, while other studies investigate its role in improving physical function in breast cancer survivors (Ji et al., 2026). These developments underscore fisetin's potential across multiple therapeutic areas, with continued research focusing on optimizing its delivery and expanding its clinical applications.